Molecular Insights into Cancer Therapeutics: Advances in Molecular Biology for Targeted Treatment Strategies

Dear Colleagues,

Cancer therapeutics have undergone a paradigm shift with the advent of molecular biology-driven insights. At the forefront of this revolution is the identification and targeting of specific molecular aberrations that drive tumorigenesis. As opposed to the canonical cytotoxic agents, which often present with broad systemic effects, this new generation of targeted therapies aims at the molecular Achilles' heels of individual tumors. Such strategies are based on a comprehensive understanding of oncogenic mutations, altered signaling pathways, and dysregulated epigenetic mechanisms. Noteworthy advancements include the design of small-molecule inhibitors targeting hyperactivated kinases such as BCR-ABL, EGFR, and ALK, as well as monoclonal antibodies against growth factor receptors. Additionally, the unveiling of the tumor microenvironment's complex interplay has birthed checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4, shifting the focus to modulating the host immune response. Furthermore, the integration of high-throughput sequencing technologies into clinical settings facilitates the identification of patient-specific molecular vulnerabilities. As we refine our molecular techniques and expand our understanding of tumor heterogeneity, we move closer to an era of truly personalized treatment strategies, matching patients with the most efficacious therapeutic interventions based on their tumor's molecular fingerprint.

Dr. Gerwin Heller
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• personalized medicine
• targeted therapies
• molecular classification
• precision medicine